SCHEMBL3685289

SCHEMBL3685289

CCCCC#Cc1ccc(C(=O)ON2C(=O)CCC2=O)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.47
RECQL P46063 1/20 0.47
MAPT P10636 2/20 0.44
TNK2 Q07912 1/20 0.41
KDM4E B2RXH2 2/20 0.36
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
CHRNA4 P43681 1/20 0.33
ACACB O00763 1/20 0.33
KMT2A Q03164 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
MEN1 O00255 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543909 0.78 CHRNA4 (0.43) MAPTKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL982584 0.76 KDM4E (0.61) MAPTKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL26742181 0.75 KMT2A (0.38) MAPTKDM4ELMNAALDH1A1KMT2A
SCHEMBL7733786 0.71 POLB (0.55) POLBRECQLMAPTTNK2FFAR1
SCHEMBL7739092 0.71 POLB (0.52) POLBRECQLMAPTTNK2FFAR1
SCHEMBL11065426 0.70 KMT2A (0.33) TNK2KDM4EKMT2ASMN1; SMN2
SCHEMBL3681633 0.69 KMT2A (0.45) MAPTKDM4ELMNAALDH1A1L3MBTL1
SCHEMBL3680728 0.68 THRA (0.50) MAPTALDH1A1KMT2ATDP1MEN1
SCHEMBL17071632 0.67 ALDH1A1 (0.47) POLBLMNAALDH1A1KMT2ATDP1
SCHEMBL11064022 0.66 PTPN7 (0.37) POLBRECQLMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410150-B2 Inhibitors of carnitine palmitoyltransferase and treating cancer UNIVERSITY HEALTH NETWORK (CA) 2013-04-02 US disclosed
US-20100105900-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK 2010-04-29 US disclosed
WO-2008109991-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105900-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER CPT1A, CPT1B, CPT2 POLB 1534/4885RECQL 3660/4885MAPT 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.